{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:49:01Z","timestamp":1794948541103,"version":"4.9.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.berh.2022.101805","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T06:56:33Z","timestamp":1671346593000},"page":"101805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment of rheumatic adverse events of cancer immunotherapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Pankti","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.berh.2022.101805_bib2","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2018"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10145","key":"10.1016\/j.berh.2022.101805_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","article-title":"Reporting of immune checkpoint inhibitor-associated myocarditis","volume":"392","author":"Al-Kindi","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib6","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.berh.2022.101805_bib7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib10","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"The oncologist"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10.1016\/j.berh.2022.101805_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215819","article-title":"Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?","volume":"80","author":"Raschi","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib16","first-page":"1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J\u00a0Immunother Canc"},{"issue":"18","key":"10.1016\/j.berh.2022.101805_bib17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series","volume":"66","author":"Wen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib106","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib107","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2022.101805_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.berh.2022.101805_bib21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib22","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.berh.2022.101805_bib23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib24","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"suppl_4","key":"10.1016\/j.berh.2022.101805_bib26","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"36","key":"10.1016\/j.berh.2022.101805_bib28","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101805_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","article-title":"Infectious complications in patients treated with immune checkpoint inhibitors","volume":"141","author":"Karam","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cam4.4393","article-title":"Infectious complications of immune checkpoint inhibitors in solid organ malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.berh.2022.101805_bib34","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"28","key":"10.1016\/j.berh.2022.101805_bib35","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.berh.2022.101805_bib36","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib37","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J\u00a0Immun Therr Canc"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.berh.2022.101805_bib39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J\u00a0Thorac Oncol : Off Publ Int Assoc Stud Canc"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib40","article-title":"Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade","volume":"9","author":"Beattie","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib42","doi-asserted-by":"crossref","first-page":"105168","DOI":"10.1016\/j.jbspin.2021.105168","article-title":"Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: consequences on overall survival","volume":"88","author":"Adda","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.berh.2022.101805_bib44","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib45","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib47","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101805_bib52","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib53","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib59","first-page":"175","article-title":"Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J\u00a0Immunother"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib60","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"suppl 9","key":"10.1016\/j.berh.2022.101805_bib61","article-title":"Comparing the safety and effectiveness of methotrexate, TNF and IL6 inhibitors for the treatment of checkpoint inhibitor arthritis [abstract]","volume":"74","author":"Bass","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib62","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib63","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/CMR.0b013e3283543d72","article-title":"Interleukin-6 and melanoma","volume":"22","author":"Hoejberg","year":"2012","journal-title":"Melanoma Res"},{"issue":"29","key":"10.1016\/j.berh.2022.101805_bib65","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2007.14.1978","article-title":"Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients","volume":"26","author":"Lutgendorf","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-009-0818-8","article-title":"Serum interleukin-6 levels in colorectal cancer patients--a summary of published results","volume":"25","author":"Knupfer","year":"2010","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib67","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib68","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.berh.2022.101805_bib69","doi-asserted-by":"crossref","first-page":"TPS9589","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9589","article-title":"Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma","volume":"39","author":"Mehmi","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.berh.2022.101805_bib70","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib71","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2022.04.010","article-title":"IL-6 blockade in cancer patients treated with immune checkpoint blockade: a win-win strategy","volume":"40","author":"Delyon","year":"2022","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib73","doi-asserted-by":"crossref","first-page":"e003260","DOI":"10.1136\/jitc-2021-003260","article-title":"Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study","volume":"9","author":"Reid","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib74","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib75","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib76","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade","volume":"22","author":"Naidoo","year":"2017","journal-title":"The oncologist"},{"issue":"3","key":"10.1016\/j.berh.2022.101805_bib77","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A\u00a0systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib78","article-title":"Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab","volume":"9","author":"Alexander","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib81","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/imt-2019-0085","article-title":"Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature","volume":"12","author":"Nigro","year":"2020","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.berh.2022.101805_bib82","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.berh.2022.101805_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-222628","article-title":"Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis","author":"Takeda","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib84","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database","volume":"81","author":"Nguyen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2022.101805_bib85","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101805_bib86","doi-asserted-by":"crossref","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2022.101805_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.berh.2022.101805_bib88","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/RHU.0000000000001874","article-title":"Immune checkpoint inhibitor-associated myositis: a distinct form of inflammatory myopathy","volume":"28","author":"Saygin","year":"2022","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101805_bib89","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejca.2021.08.045","volume":"157","author":"Hajem","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.berh.2022.101805_bib90","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.berh.2022.101805_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2022.101805_bib92","doi-asserted-by":"crossref","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.berh.2022.101805_bib93","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib94","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/imt-2020-0230","article-title":"The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases","volume":"13","author":"Wu","year":"2021","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib96","first-page":"327","article-title":"Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group","volume":"71","author":"Fountzilas","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.berh.2022.101805_bib98","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard-2022-222186","article-title":"Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study","volume":"81","author":"Placais","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2022.101805_bib99","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"The oncologist"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.berh.2022.101805_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.berh.2022.101805_bib102","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.berh.2022.101805_bib103","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2022.101805_bib104","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21037\/hbsn-22-143","article-title":"Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.berh.2022.101805_bib105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422200064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422200064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:42Z","timestamp":1761499362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422200064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S152169422200064X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101805","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of rheumatic adverse events of cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101805"}}